MDAI

Spectral AI Inc. Class A Common Stock (MDAI) | Rumor.io

Spectral AI

MDAI

Attention (50-day avg)0%

Attention rank (50-day avg)#2,106

Bullish sentiment (50-day avg)79%

Price to earnings ratio29.7

Market capitalization51.8M

Earnings per share-0.32

Dividend yield (TTM)—

Revenue (annual)19.6M

Net income (annual)-7.6M

Social

What share of all stock conversation is about MDAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 13

$MDAI has shown a strong day, potentially indicating a positive trend, and may see further growth by year's end.
The company's valuation has been raised to 6.25, and some investors are optimistic about sales and the company's confidence in its product.
A significant volume increase following an earnings call is a positive sign, and some investors believe a commercial sales announcement could be the catalyst for further growth.

Generated by AI

Sentiment

Of the messages about MDAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	66.67% -20	78.79% -0.44	83.16% -0.67
Bearish	—	33.33% +20	21.21% +0.44	16.84% +0.67

Bullish· May 27

The FDA has approved Spectral AI's DeepView, allowing the company to start generating revenue and potentially leading to a significant increase in value.
BTIG analyst Ryan Zimmerman has upgraded his price target for Spectral AI from $3 to $4, citing a potential upside of 68.78% and a rating of Buy.
The company's FDA approval and government backing make it an attractive acquisition target, with a potential sale price of up to $4.50 per share and a total acquisition cost of around $145 million.

Bearish· May 29

The company's focus on burn centers, trauma centers, and emergency departments may be a smart initial strategy, but launching broadly into all wound care immediately could fail.
The stock's price is a gift, and the company needs to capitalize and scale quickly to take advantage of the opportunity.
The company's management has not effectively managed sentiment and communicated the potential of the company's FDA approval and guaranteed government sales, which has led to a negative market reaction.

Generated by AI

Topics

Of the messages about MDAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	36.36%	26.78%
Announcements	—	—	36.36%	29.57%
Earnings	—	—	0%	9.66%
Macro	—	—	27.27%	20.87%
Analysts	—	—	0%	13.13%
Controversies	—	—	0%	0%

Announcements· May 24

Spectral AI (MDAI) received FDA approval for its DeepView imaging system, a burn wound analysis machine, which can now be sold in the US market.
The company plans to commercialize the system first, followed by expansion to accommodate other applications, such as diabetic foot ulcers.
MDAI has a backlog of device placements from the ABA burn conference and has secured orders from BARDA for 170 devices, indicating strong demand for the technology.

Technical Analysis· Dec 2

The 9-day upper Bollinger Band is a key resistance level for $MDAI, currently at $2.50, and has been breached on high volume, indicating a strong bullish signal.
The stock is experiencing a powerful uptrend, with the upper Bollinger Band serving as a catalyst for price action, and a break above $2.75 could lead to a new 52-week high.
$MDAI is overbought, with an RSI of 76, and a small consolidation could be healthy, but the stock is still riding the uptrend train and has the potential for further gains.

Generated by AI

Community

Of the messages about MDAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	33.33%	68.42%	56.86%
Newcomers	100%	66.67%	31.58%	43.14%

Regulars· Aug 12

The regulars are focused on the potential for Spectral AI's DeepView to be adopted by hospitals, with some installations expected in Q4 2026 and a business model that includes capital purchase/lease and recurring software and services.
The BARDA funding is seen as a positive development, but the stock price and Q2 EPS won't automatically "catch up" until actual commercial deployments and revenue start showing up, and the lack of preparation or readiness to take DeepView to market is a concern.
The regulars are also discussing the vulnerability of Spectral AI as a small corporation compared to the giants in the AI industry, and the potential for Spectral AI to be left behind by the larger companies if they don't take advantage of their current opportunities.

Newcomers· May 27

Many newcomers are questioning the thesis on MDAI, citing institutional selling and the stock's drop despite FDA approval, wondering if it's a buying opportunity.
Concerns are raised about Hudson Bay's involvement with MDAI, with some users expressing worry about the company's financial situation and others seeing it as a temporary dilution opportunity.
Some users are waiting to reinvest in MDAI due to concerns about Hudson Bay's agreements and the potential impact on the company's fundamentals, while others see it as an opportunity to enter the stock before it shoots up.

Generated by AI

News

Spectral AI, Inc. Q2 2026 Earnings Call Summary

Moby summary of Spectral AI, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Spectral AI earnings beat by $0.02, revenue fell short of estimates

1mo agoInvesting.com

Spectral AI Q2 Earnings Call Highlights

Spectral AI (NASDAQ:MDAI) said its second-quarter results marked a transition toward commercial operations following the U.S. Food and Drug Administration’s De Novo clearance of its DeepView System for burn assessment in May. The company reiterated its 2026 revenue guidance of approximately $18.5 mi

1mo agoYahoo Finance

Earnings call transcript: Spectral AI posts smaller Q2 2026 loss, shares fall after hours

1mo agoInvesting.com

Spectral AI Announces 2026 Second Quarter Financial Results

Company Continues to Advance Towards First Commercial Sales of the DeepView® System for Burn Indication

1mo agoBarchart.com

Earnings To Watch: Spectral AI Inc (MDAI) Q2 2026 -- GF Value Sees 60% Downside

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

1mo agoYahoo Finance

Also Discussed

Investors talking about MDAI also mention

#	Name	Attention
1	LIPO - Lipella Pharmaceuticals Inc.	——
2	BNOX - Bionomics Limited	——
3	Femasys Inc.FEMY	0%+0
4	PaxMedica Inc.PXMD	0%0
5	MINM - Minim, Inc.	——
6	SECO - Secoo Holding Limited	——
7	Donaldson Company, Inc.DCI	0%0
8	ParaZero Technologies Ltd.PRZO	0%+0
9	Intelligent Bio Solutions Inc.INBS	0%0
10	INNO - Harbor Disruptive Innovation ETF	——

Spectral AI Inc. Class A Common Stock

Healthcare
Medical Devices

Spectral AI Inc. Class A Common Stock represents Spectral AI Inc., an artificial intelligence company focused on predictive medical diagnostics for wound care. The company’s DeepView platform is designed to help clinicians assess wound healing potential before treatment by using proprietary AI and multispectral imaging to distinguish between damaged and healthy tissue. Its current work centers on supporting faster, more objective treatment decisions in burn care and diabetic foot ulcer applications, with additional clinical uses in development. Spectral AI serves the healthcare technology market by combining imaging, software, and diagnostic analysis into tools intended for physician use in hospital and clinical settings. Headquartered in Dallas, Texas, Spectral AI operates as a specialized medical technology business within the broader digital health and medical devices sector.

Website

Location

2515 McKinney Avenue

Dallas, TX, 75201

United States

Social

What share of all stock conversation is about MDAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Aug 13

$MDAI has shown a strong day, potentially indicating a positive trend, and may see further growth by year's end.
The company's valuation has been raised to 6.25, and some investors are optimistic about sales and the company's confidence in its product.
A significant volume increase following an earnings call is a positive sign, and some investors believe a commercial sales announcement could be the catalyst for further growth.

Generated by AI

Sentiment

Of the messages about MDAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	66.67% -20	78.79% -0.44	83.16% -0.67
Bearish	—	33.33% +20	21.21% +0.44	16.84% +0.67

Bullish· May 27

The FDA has approved Spectral AI's DeepView, allowing the company to start generating revenue and potentially leading to a significant increase in value.
BTIG analyst Ryan Zimmerman has upgraded his price target for Spectral AI from $3 to $4, citing a potential upside of 68.78% and a rating of Buy.
The company's FDA approval and government backing make it an attractive acquisition target, with a potential sale price of up to $4.50 per share and a total acquisition cost of around $145 million.

Bearish· May 29

The company's focus on burn centers, trauma centers, and emergency departments may be a smart initial strategy, but launching broadly into all wound care immediately could fail.
The stock's price is a gift, and the company needs to capitalize and scale quickly to take advantage of the opportunity.
The company's management has not effectively managed sentiment and communicated the potential of the company's FDA approval and guaranteed government sales, which has led to a negative market reaction.

Generated by AI

Topics

Of the messages about MDAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	36.36%	26.78%
Announcements	—	—	36.36%	29.57%
Earnings	—	—	0%	9.66%
Macro	—	—	27.27%	20.87%
Analysts	—	—	0%	13.13%
Controversies	—	—	0%	0%

Announcements· May 24

Spectral AI (MDAI) received FDA approval for its DeepView imaging system, a burn wound analysis machine, which can now be sold in the US market.
The company plans to commercialize the system first, followed by expansion to accommodate other applications, such as diabetic foot ulcers.
MDAI has a backlog of device placements from the ABA burn conference and has secured orders from BARDA for 170 devices, indicating strong demand for the technology.

Technical Analysis· Dec 2

The 9-day upper Bollinger Band is a key resistance level for $MDAI, currently at $2.50, and has been breached on high volume, indicating a strong bullish signal.
The stock is experiencing a powerful uptrend, with the upper Bollinger Band serving as a catalyst for price action, and a break above $2.75 could lead to a new 52-week high.
$MDAI is overbought, with an RSI of 76, and a small consolidation could be healthy, but the stock is still riding the uptrend train and has the potential for further gains.

Generated by AI

Community

Of the messages about MDAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	33.33%	68.42%	56.86%
Newcomers	100%	66.67%	31.58%	43.14%

Regulars· Aug 12

The regulars are focused on the potential for Spectral AI's DeepView to be adopted by hospitals, with some installations expected in Q4 2026 and a business model that includes capital purchase/lease and recurring software and services.
The BARDA funding is seen as a positive development, but the stock price and Q2 EPS won't automatically "catch up" until actual commercial deployments and revenue start showing up, and the lack of preparation or readiness to take DeepView to market is a concern.
The regulars are also discussing the vulnerability of Spectral AI as a small corporation compared to the giants in the AI industry, and the potential for Spectral AI to be left behind by the larger companies if they don't take advantage of their current opportunities.

Newcomers· May 27

Many newcomers are questioning the thesis on MDAI, citing institutional selling and the stock's drop despite FDA approval, wondering if it's a buying opportunity.
Concerns are raised about Hudson Bay's involvement with MDAI, with some users expressing worry about the company's financial situation and others seeing it as a temporary dilution opportunity.
Some users are waiting to reinvest in MDAI due to concerns about Hudson Bay's agreements and the potential impact on the company's fundamentals, while others see it as an opportunity to enter the stock before it shoots up.

Generated by AI

Spectral AI

Social

Aug 13

Bullish· May 27

Bearish· May 29

Announcements· May 24

Technical Analysis· Dec 2

Regulars· Aug 12

Newcomers· May 27

Spectral AI, Inc. Q2 2026 Earnings Call Summary

Spectral AI earnings beat by $0.02, revenue fell short of estimates

Spectral AI Q2 Earnings Call Highlights

Earnings call transcript: Spectral AI posts smaller Q2 2026 loss, shares fall after hours

Spectral AI Announces 2026 Second Quarter Financial Results

Earnings To Watch: Spectral AI Inc (MDAI) Q2 2026 -- GF Value Sees 60% Downside

Also Discussed

Spectral AI Inc. Class A Common Stock

Company Information

Location

Spectral AI, Inc. Q2 2026 Earnings Call Summary

Spectral AI earnings beat by $0.02, revenue fell short of estimates

Spectral AI Q2 Earnings Call Highlights

Earnings call transcript: Spectral AI posts smaller Q2 2026 loss, shares fall after hours

Spectral AI Announces 2026 Second Quarter Financial Results

Earnings To Watch: Spectral AI Inc (MDAI) Q2 2026 -- GF Value Sees 60% Downside

Also Discussed

Social

Aug 13

Bullish· May 27

Bearish· May 29

Announcements· May 24

Technical Analysis· Dec 2

Regulars· Aug 12

Newcomers· May 27